342 related articles for article (PubMed ID: 19563206)
1. Interpretation and considerations on the safety evaluation of human drug metabolites.
Atrakchi AH
Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
[TBL] [Abstract][Full Text] [Related]
2. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
3. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
4. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
[TBL] [Abstract][Full Text] [Related]
5. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
Smith DA; Obach RS
Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
[TBL] [Abstract][Full Text] [Related]
6. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
[TBL] [Abstract][Full Text] [Related]
8. Predicting circulating human metabolites: how good are we?
Anderson S; Luffer-Atlas D; Knadler MP
Chem Res Toxicol; 2009 Feb; 22(2):243-56. PubMed ID: 19138063
[TBL] [Abstract][Full Text] [Related]
9. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
Prueksaritanont T; Lin JH; Baillie TA
Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
[TBL] [Abstract][Full Text] [Related]
10. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
Zhu M; Zhang D; Zhang H; Shyu WC
Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
[TBL] [Abstract][Full Text] [Related]
11. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
Baillie TA
Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
[TBL] [Abstract][Full Text] [Related]
12. Strategy for genotoxicity testing--metabolic considerations.
Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
[TBL] [Abstract][Full Text] [Related]
13. Introduction: Human metabolites in safety testing (MIST) issue.
Guengerich FP
Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
[No Abstract] [Full Text] [Related]
14. Metabolites and safety: What are the concerns, and how should we address them?
Smith DA; Obach RS
Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
[TBL] [Abstract][Full Text] [Related]
15. Overview of metabolite safety testing from an industry perspective.
Anderson S; Knadler MP; Luffer-Atlas D
Bioanalysis; 2010 Jul; 2(7):1249-61. PubMed ID: 21083238
[TBL] [Abstract][Full Text] [Related]
16. Human radiolabeled mass balance studies: objectives, utilities and limitations.
Penner N; Klunk LJ; Prakash C
Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
[TBL] [Abstract][Full Text] [Related]
17. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
[TBL] [Abstract][Full Text] [Related]
18. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
19. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
Yu H; Tweedie D
Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
[TBL] [Abstract][Full Text] [Related]
20. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
Srinivas NR
Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
